The Peter Schick Foundation has submitted its request for an IND Number from the FDA

The Peter Schick Foundation has submitted all the necessary data to obtain an IND number from the FDA for the product Alpha Sun. Alpha Sun is made by Simplexity Health of Klamath Falls, Oregon. The product, a bone marrow stem cell stimulator, increases the number of circulating stem cells 20-30% two hours after oral ingestion of l000mg/day. The foundation hopes to test the product in a number of clinical studies, namely Type 2 Diabetes and HIV+ patients who are virologically suppressed on antiretroviral therapy. Additional studies in the works include testing the product in osteoarthitis patients, osteoporosis patients, prostatitis patients, Acne patients, post-operative inguinal hernia patients, carpal tunnel patients, and Cardiac rehabilitation patients. The product has significant anti inflammatory capabilities, is a mood elevator, and has a carbohydrate that directs bone marrow stem cells to the point of inflammation and injury where it initiates repair of damage caused by an inflammatory process. Two initial trials will be done for Type 2 Diabetes, and another for HIV+ patients who are virologically suppressed on antiretroviral therapy.

The Peter Schick Foundation and Simplexity Health are forming a partnership to study in clinical trials Aphanizomenon Flos-Aquae (termed AFA), which is the major component of the product Alpha Sun.

A C corporation will be formed with available common shares of stock. If you wish to learn more about the offering or donate to the non-profit 501(c)(3) foundation, please email schickpm@aol.com or contribute by mail to the Schick Foundation, 1223 Wilshire Blvd. #1007, Santa Monica, CA 90403.